To further contextualize these findings, the inhibition of TGF-β1 signaling observed with GDP parallels the mechanism targeted by clinical antifibrotic agents such as pirfenidone, which is currently approved for idiopathic pulmonary fibrosis and under investigation for hepatic fibrosis. This evidence concerns the gene TGFB1 and pulmonary fibrosis.